Literature DB >> 14499226

International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2.

Milan Gupta1, Wei-Ching Chang, Frans Van de Werf, Christopher B Granger, William Midodzi, Gabriel Barbash, Kenneth Pehrson, Ali Oto, Pavlos Toutouzas, Petr Jansky, Paul W Armstrong.   

Abstract

BACKGROUND: Revascularization rates vary substantially between countries in patients with acute ST-elevation myocardial infarction (STEMI). The impact of early revascularization on clinical outcomes in such patients remains uncertain. The ASSENT-2 fibrinolytic trial provides the opportunity to compare revascularization rates following STEMI in patients across 29 countries, and to explore the relationship between revascularization and clinical outcome.
METHODS: Countries participating in ASSENT-2 were grouped into tertiles according to their in-hospital revascularization rates (<15%, 15-39%, >39%). Baseline characteristics, medication and procedure use, and clinical outcomes of the 16949 patients enrolled were compared. Multiple Cox regressions were used to assess the relationship between the tertiles and 30-day mortality, the primary endpoint of the ASSENT-2 trial. Multilevel logistic regression models were developed to validate and further extend the findings from the single-level analyses.
RESULTS: Patients in highest tertile countries were younger, heavier, and more often diabetic or hypertensive. They were more likely to have had a previous myocardial infarction or revascularization procedure. Time to treatment and hospital length of stay were shorter in the highest tertile, and beta-blocker use was more frequent. Stroke rates were low and similar across tertiles, with no statistically significant difference in rates of intracranial haemorrhage. Recurrent ischaemia and reinfarction were less common in the highest tertile. Mortality rates at 30 days were lower for countries with the highest revascularization rates (5.1% vs 6.9% vs 6.5% for the lower two tertiles, P<0.001). At 1 year, mortality remained significantly lower in the highest tertile countries (8.4% vs 10.6% vs 9.9%, P=0.001). Following adjustment for baseline patient characteristics, Cox regression analysis confirmed an excess of 30-day and 1-year mortality in the lowest and intermediate tertiles compared to the highest tertile. The multilevel analyses validated these findings, and demonstrated that a country's life expectancy and the hospital volume were inversely related to both 30-day and 1-year mortality.
CONCLUSIONS: The highest rate of in-hospital revascularization following fibrinolytic therapy for acute myocardial infarction in this international study was associated with a reduction in recurrent ischaemia, reinfarction, and improved survival at both 30 days and at 1 year. The optimal rates of revascularization in this setting remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499226     DOI: 10.1016/s0195-668x(03)00433-0

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  International comparison of treatment and long-term outcomes for acute myocardial infarction in the elderly: Minneapolis/St. Paul, MN, USA and Goteborg, Sweden.

Authors:  Lindsay G Smith; Johan Herlitz; Thomas Karlsson; Alan K Berger; Russell V Luepker
Journal:  Eur Heart J       Date:  2013-06-25       Impact factor: 29.983

Review 2.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis.

Authors:  Wei-Ching Chang; William K Midodzi; Cynthia M Westerhout; Eric Boersma; Judith Cooper; Elliot S Barnathan; Maarten L Simoons; Lars Wallentin; E Magnus Ohman; Paul W Armstrong
Journal:  J Epidemiol Community Health       Date:  2005-05       Impact factor: 3.710

Review 4.  Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.

Authors:  Eden Liu; Leon Hsueh; Hajwa Kim; Mladen I Vidovich
Journal:  Am Heart J       Date:  2017-09-08       Impact factor: 4.749

Review 5.  Drug-eluting stents versus bare-metal stents for acute coronary syndrome.

Authors:  Joshua Feinberg; Emil Eik Nielsen; Janette Greenhalgh; Juliet Hounsome; Naqash J Sethi; Sanam Safi; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2017-08-23

6.  Multilevel Analysis of Factors Associated with Treatment-Seeking Behaviors among Caregivers with Febrile Children in Malawi.

Authors:  Owen Nkoka; Ting-Wu Chuang; Yi-Hua Chen
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

Review 7.  Inequalities in care in patients with acute myocardial infarction.

Authors:  Shabnam Rashid; Alexander Simms; Phillip Batin; John Kurian; Chris P Gale
Journal:  World J Cardiol       Date:  2015-12-26

8.  Analytical method development and validation of prasugrel in bulk and its pharmaceutical formulation using the RP-HPLC method.

Authors:  B Mohammed Ishaq; K Vanitha Prakash; G Krishna Mohan
Journal:  Pharm Methods       Date:  2011-07

9.  Outcomes following percutaneous coronary intervention and coronary artery bypass grafting surgery in Chinese, South Asian and White patients with acute myocardial infarction: administrative data analysis.

Authors:  Danijela Gasevic; Nadia A Khan; Hong Qian; Shahzad Karim; Gerald Simkus; Hude Quan; Martha H Mackay; Blair J O'Neill; Amir F Ayyobi
Journal:  BMC Cardiovasc Disord       Date:  2013-12-26       Impact factor: 2.298

10.  Predictive Factors of Hospital Mortality Due to Myocardial Infarction: A Multilevel Analysis of Iran's National Data.

Authors:  Ali Ahmadi; Hamid Soori; Yadollah Mehrabi; Koorosh Etemad; Homeira Sajjadi; Mehraban Sadeghi
Journal:  Int J Prev Med       Date:  2015-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.